Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 6, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2016-11-02
DOI
10.3389/fonc.2016.00233
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis
- (2016) D. Mittal et al. CANCER RESEARCH
- CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination
- (2016) T. Ahrends et al. CANCER RESEARCH
- Systematic review of case reports on the abscopal effect
- (2016) Yazan Abuodeh et al. CURRENT PROBLEMS IN CANCER
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Synergy between chemotherapy and cancer vaccination
- (2015) Tetje C. van der Sluis et al. Aging-US
- Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
- (2015) Suzanne L. Topalian et al. CANCER CELL
- Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges
- (2015) Feifei Teng et al. CANCER LETTERS
- Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma
- (2015) David L. Bajor et al. CANCER RESEARCH
- TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity
- (2015) Claire Vanpouille-Box et al. CANCER RESEARCH
- CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
- (2015) Martin Turcotte et al. CANCER RESEARCH
- Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
- (2015) Sonja Kleffel et al. CELL
- CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer
- (2015) B. G. Leclerc et al. CLINICAL CANCER RESEARCH
- The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
- (2015) L. Liu et al. CLINICAL CANCER RESEARCH
- Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential
- (2015) Koen van de Ven et al. Immunotherapy
- Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma
- (2015) Douglas B Johnson et al. Immunotherapy
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- CTLA-4 Blockade Plus Adoptive T-Cell Transfer Promotes Optimal Melanoma Immunity in Mice
- (2015) David A. Mahvi et al. JOURNAL OF IMMUNOTHERAPY
- PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
- (2015) Kevin C. Soares et al. JOURNAL OF IMMUNOTHERAPY
- Abstract A90: Combination therapy of chemokine receptor inhibition plus PDL-1 blockade potentiates anti-tumor effects in a murine model of breast cancer
- (2015) Heiyoun Jung MOLECULAR CANCER THERAPEUTICS
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
- (2015) Xiaojuan Liu et al. NATURE MEDICINE
- 143 The Combination of anti-TIM-3 and anti-PD-1 Checkpoint Inhibitors With Focused Radiation Resulted in a Synergistic Antitumor Immune Response in a Preclinical Glioma Model
- (2015) Jennifer E. Kim et al. NEUROSURGERY
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab
- (2015) David R. Minor et al. Pigment Cell & Melanoma Research
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
- (2015) Jun Liu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment
- (2015) Claire Vanpouille-Box et al. VACCINE
- Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment
- (2015) A. Zippelius et al. Cancer Immunology Research
- Adenosine Receptor 2A Blockade Increases the Efficacy of Anti–PD-1 through Enhanced Antitumor T-cell Responses
- (2015) Paul A. Beavis et al. Cancer Immunology Research
- Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs
- (2015) Kea Martin et al. Frontiers in Immunology
- Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
- (2015) Erika Héninger et al. Frontiers in Immunology
- Combinatorial Strategies for the Induction of Immunogenic Cell Death
- (2015) Lucillia Bezu et al. Frontiers in Immunology
- CD73: A potential biomarker for anti-PD-1 therapy
- (2015) Paul A Beavis et al. OncoImmunology
- Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models
- (2015) A Covre et al. OncoImmunology
- Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma
- (2015) James Larkin et al. JAMA Oncology
- Role of Local Radiation Therapy in Cancer Immunotherapy
- (2015) Sandra Demaria et al. JAMA Oncology
- Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers
- (2015) Tara C Gangadhar et al. Journal for ImmunoTherapy of Cancer
- A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265)
- (2015) Georgina V Long et al. Journal for ImmunoTherapy of Cancer
- Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
- (2015) Danielle M Lussier et al. Journal for ImmunoTherapy of Cancer
- 2015: The Year of Anti-PD-1/PD-L1s Against Melanoma and Beyond
- (2015) Paolo A. Ascierto et al. EBioMedicine
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity
- (2015) Todd Bartkowiak et al. Frontiers in Oncology
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- Blockade of PD-1/PD-L1 Promotes Adoptive T-Cell Immunotherapy in a Tolerogenic Environment
- (2015) Stephen J. P. Blake et al. PLoS One
- A General Functional Response of Cytotoxic T Lymphocyte-Mediated Killing of Target Cells
- (2014) Saikrishna Gadhamsetty et al. BIOPHYSICAL JOURNAL
- The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
- (2014) Robert J. Johnston et al. CANCER CELL
- Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
- (2014) D. Mittal et al. CANCER RESEARCH
- Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma
- (2014) G. T. Gibney et al. CLINICAL CANCER RESEARCH
- Vaccine-Induced Tumor Necrosis Factor-Producing T Cells Synergize with Cisplatin to Promote Tumor Cell Death
- (2014) T. C. van der Sluis et al. CLINICAL CANCER RESEARCH
- Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors
- (2014) D. A. Wainwright et al. CLINICAL CANCER RESEARCH
- Therapeutic use of anti-CTLA-4 antibodies
- (2014) C. U. Blank et al. INTERNATIONAL IMMUNOLOGY
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Combining Targeted Therapy With Immunotherapy inBRAF-Mutant Melanoma: Promise and Challenges
- (2014) Siwen Hu-Lieskovan et al. JOURNAL OF CLINICAL ONCOLOGY
- Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs
- (2014) Lei Lu et al. Journal of Translational Medicine
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer
- (2014) Zhiqiang Guo et al. PLoS One
- Focal Radiation Therapy Combined with 4-1BB Activation and CTLA-4 Blockade Yields Long-Term Survival and a Protective Antigen-Specific Memory Response in a Murine Glioma Model
- (2014) Zineb Belcaid et al. PLoS One
- The Optimal Partnership of Radiation and Immunotherapy: from Preclinical Studies to Clinical Translation
- (2014) Sandra Demaria et al. RADIATION RESEARCH
- Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response
- (2014) P. Kvistborg et al. Science Translational Medicine
- Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
- (2014) S. L. Highfill et al. Science Translational Medicine
- Stereotactic Radiation Therapy Augments Antigen-Specific PD-1-Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
- (2014) A. B. Sharabi et al. Cancer Immunology Research
- Killer Immunoglobulin-like Receptors and Tumor Immunity
- (2014) D. M. Benson et al. Cancer Immunology Research
- MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
- (2014) L. J. Vella et al. Cancer Immunology Research
- VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer Immunotherapy
- (2014) J. L. Lines et al. Cancer Immunology Research
- Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
- (2014) J. Yuan et al. Cancer Immunology Research
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
- (2014) S. Chen et al. Cancer Immunology Research
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
- (2014) Z. A. Cooper et al. Cancer Immunology Research
- Does the Immune System Naturally Protect Against Cancer?
- (2014) Alexandre Corthay Frontiers in Immunology
- TLR Agonists for Cancer Immunotherapy: Tipping the Balance between the Immune Stimulatory and Inhibitory Effects
- (2014) Hailing Lu Frontiers in Immunology
- Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment
- (2014) Stefani Spranger et al. Journal for ImmunoTherapy of Cancer
- Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma
- (2014) Howard L Kaufman et al. Journal for ImmunoTherapy of Cancer
- Combinations of Immunotherapy and Radiation in Cancer Therapy
- (2014) Ralph E. Vatner et al. Frontiers in Oncology
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
- (2013) J. Duraiswamy et al. CANCER RESEARCH
- Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
- (2013) B. Allard et al. CLINICAL CANCER RESEARCH
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma
- (2013) D. T. Frederick et al. CLINICAL CANCER RESEARCH
- Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
- (2013) L. B. John et al. CLINICAL CANCER RESEARCH
- Biological Consequences of Radiation-induced DNA Damage: Relevance to Radiotherapy
- (2013) M.E. Lomax et al. CLINICAL ONCOLOGY
- Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology
- (2013) Michael Kalos et al. IMMUNITY
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
- (2013) Laurence Zitvogel et al. IMMUNITY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Anti-CD73 therapy impairs tumor angiogenesis
- (2013) Bertrand Allard et al. INTERNATIONAL JOURNAL OF CANCER
- Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas
- (2013) Jing Zeng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Long-lasting Complete Regression of Established Mouse Tumors by Counteracting Th2 Inflammation
- (2013) Min Dai et al. JOURNAL OF IMMUNOTHERAPY
- Proposed mechanisms of action for prostate cancer vaccines
- (2013) Sean M. Geary et al. Nature Reviews Urology
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Availability of a Functional Tumor Targeting T-Cell Repertoire Determines the Anti-Tumor Efficiency of Combination Therapy with Anti-CTLA-4 and Anti-4-1BB Antibodies
- (2013) Benjamin A. H. Jensen et al. PLoS One
- Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte Responses
- (2013) Li-Xin Wang et al. PLoS One
- CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer
- (2013) S. Loi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans
- (2013) D. Sugiyama et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity
- (2013) W. L. Redmond et al. Cancer Immunology Research
- An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer
- (2013) E. B. Golden et al. Cancer Immunology Research
- Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial†
- (2012) M. Reck et al. ANNALS OF ONCOLOGY
- Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma
- (2012) Richard Wu et al. CANCER JOURNAL
- PD-1 Blockade Enhances T-cell Migration to Tumors by Elevating IFN- Inducible Chemokines
- (2012) W. Peng et al. CANCER RESEARCH
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- Suppressing T cell motility induced by anti–CTLA-4 monotherapy improves antitumor effects
- (2012) Maria Grazia Ruocco et al. JOURNAL OF CLINICAL INVESTIGATION
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells
- (2012) Y. Shirota et al. JOURNAL OF IMMUNOLOGY
- Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial
- (2012) Alfons JM van den Eertwegh et al. LANCET ONCOLOGY
- Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells
- (2012) D.-K. Chang et al. MOLECULAR CANCER THERAPEUTICS
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Subversion of the chemotherapy-induced anticancer immune response by the ecto-ATPase CD39
- (2012) Mickaël Michaud et al. OncoImmunology
- Radiation as an immunological adjuvant: current evidence on dose and fractionation
- (2012) Sandra Demaria et al. Frontiers in Oncology
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape
- (2011) S.-R. Woo et al. CANCER RESEARCH
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
- (2011) Li Wang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse Models
- (2011) D. B. Flies et al. JOURNAL OF IMMUNOLOGY
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- γ-Radiation Promotes Immunological Recognition of Cancer Cells through Increased Expression of Cancer-Testis Antigens In Vitro and In Vivo
- (2011) Anu Sharma et al. PLoS One
- Autophagy-Dependent Anticancer Immune Responses Induced by Chemotherapeutic Agents in Mice
- (2011) M. Michaud et al. SCIENCE
- Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma
- (2010) Brian I. Rini et al. CANCER
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis
- (2010) J. Stagg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor-infiltrating NY-ESO-1–specific CD8+T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer
- (2010) Junko Matsuzaki et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Clinical Experiences With Anti-CD137 and Anti-PD1 Therapeutic Antibodies
- (2010) Paolo A. Ascierto et al. SEMINARS IN ONCOLOGY
- Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment
- (2009) Y. Lee et al. BLOOD
- Dendritic Cell Vaccination Combined with CTLA4 Blockade in Patients with Metastatic Melanoma
- (2009) A. Ribas et al. CLINICAL CANCER RESEARCH
- Anti-Programmed Death-1 Synergizes with Granulocyte Macrophage Colony-Stimulating Factor-Secreting Tumor Cell Immunotherapy Providing Therapeutic Benefit to Mice with Established Tumors
- (2009) B. Li et al. CLINICAL CANCER RESEARCH
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
- (2009) Loise M. Francisco et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies
- (2009) Karl S. Peggs et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Functionally Distinct LAG-3 and PD-1 Subsets on Activated and Chronically Stimulated CD8 T Cells
- (2009) J. F. Grosso et al. JOURNAL OF IMMUNOLOGY
- A2A Adenosine Receptor May Allow Expansion of T Cells Lacking Effector Functions in Extracellular Adenosine-Rich Microenvironments
- (2009) A. Ohta et al. JOURNAL OF IMMUNOLOGY
- Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection
- (2008) R. Brad Jones et al. JOURNAL OF EXPERIMENTAL MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search